IGC Pharma financials
$0.2675−2.37%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q3 '25 Dec 31 | Q4 '24 Mar 31 | Q3 '24 Dec 31 | Q2 '24 Sep 30 | Q1 '24 Jun 30 | Q4 '23 Mar 31 | Q3 '23 Dec 31 | Q2 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $265.0K | $317.0K | $328.0K | $330.0K | $257.0K | $295.0K | $204.0K | $291.0K | $555.0K | $166.0K | $332.0K | $202.0K |
| Gross profit | $48.0K | $55.0K | $154.0K | $154.0K | $104.0K | $171.0K | $133.0K | $174.0K | $255.0K | $63.0K | $102.0K | $135.0K |
| Gross margin | 18.1% | 17.4% | 47.0% | 46.7% | 40.5% | 58.0% | 65.2% | 59.8% | 45.9% | 38.0% | 30.7% | 66.8% |
| Operating income | -$2.8M | -$2.5M | -$1.9M | -$1.4M | -$1.9M | $453.0K | -$5.6M | -$2.5M | -$2.1M | -$4.0M | -$2.3M | -$2.5M |
| Net income | -$2.9M | -$2.4M | -$1.6M | -$1.2M | -$1.8M | -$2.9M | -$5.6M | -$2.5M | -$2.1M | -$4.0M | -$2.2M | -$2.4M |
| Net margin | −1107.9% | −757.7% | −487.5% | −363.0% | −711.7% | −978.0% | −2739.7% | −842.3% | −373.9% | −2427.7% | −677.4% | −1208.9% |
| Diluted EPS | $-0.03 | $-0.02 | $-0.02 | $-0.02 | $-0.02 | $-0.04 | $-0.09 | $-0.05 | $-0.04 | $-0.08 | $-0.04 | $-0.05 |
| EBITDA | -$2.7M | -$2.4M | -$1.8M | -$1.3M | -$1.7M | -$2.0M | -$2.8M | -$2.3M | -$2.0M | -$3.9M | -$2.1M | -$2.3M |
| Operating cash flow | -$1.4M | -$1.2M | -$1.4M | -$730.0K | -$1.3M | -$526.0K | -$1.6M | -$1.6M | -$1.5M | -$1.5M | -$1.6M | -$1.7M |
| Free cash flow | -$1.4M | -$1.2M | -$1.4M | -$748.0K | -$1.3M | -$541.0K | -$1.7M | -$1.7M | -$1.5M | -$1.8M | -$1.6M | -$1.8M |
| Diluted shares | 100.3M | 98.2M | 83.0M | 79.7M | 77.6M | 64.3M | 63.7M | 54.3M | 53.1M | 53.4M | 53.1M | 52.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Dec 31 | Sep 30 | Jun 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $331.0K | $207.0K | $900.0K | $470.0K | $1.5M | $1.8M |
| Short-term investments | $23.0K | $28.0K | $38.0K | $0.00 | $0.00 | $0.00 |
| Total debt | $1.1M | $917.0K | $311.0K | $134.0K | $135.0K | $136.0K |
| Total assets | $9.5M | $9.2M | $9.7M | $9.1M | $10.4M | $10.6M |
| Total liabilities | $3.4M | $3.1M | $2.3M | $2.8M | $3.0M | $2.7M |
| Shareholders' equity | $6.1M | $6.1M | $7.4M | $6.3M | $7.4M | $7.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology